NEW BRUNSWICK, N.J. — Johnson & Johnson announced last Thursday it will expand its U.S. footprint with a new 160,000-square-foot dedicated manufacturing facility at Fujifilm’s biopharmaceutical campus in Holly Springs.
The $2 billion commitment over the next decade will bolster the company’s U.S. manufacturing capacity and create about 120 new jobs in North Carolina.
In the months ahead, Johnson & Johnson said it plans to unveil additional advanced manufacturing sites in the U.S. while also expanding its existing facilities. The company said the moves will strengthen its ability to produce the majority of its advanced medicines domestically and meet patient needs across the country.
“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, chairman and chief executive officer. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”
The Holly Springs facility adds to a growing list of investments Johnson & Johnson is making in North Carolina. In March, the company announced a $55 billion commitment to support U.S. manufacturing, research and development, and technology initiatives over the next four years.
Construction is already underway at a site in Wilson, which will employ more than 500 people once complete and generate roughly 5,000 construction jobs during development.
The company said its broader investment strategy also includes expanded research and development infrastructure focused on oncology, neuroscience, immunology, cardiovascular disease and robotic surgery.
By partnering with Fujifilm on the Holly Springs campus, Johnson & Johnson said it will gain access to one of the most advanced biopharmaceutical manufacturing hubs in the country. The move is expected to further expand production capacity while supporting thousands of jobs nationwide.
